Simplified Process Based on a Single Plasmid

AAVnerGene Inc., a gene therapy company based in Maryland, USA, has officially launched 'AAVone® 2.1', its next-generation adeno-associated virus (AAV) production platform. Existing AAV manufacturing processes primarily employ a triple-plasmid transient transfection method, which is complex and suffers from significant batch-to-batch variability. The newly developed AAVone® 2.1 integrates these three elements into a single plasmid, significantly simplifying the production process. This streamlined process is expected to eliminate errors during manufacturing and maximize the stability of virus vector supply in the short term.

Achieving High Purity with 1e16 GC/L and Over 70% Full Capsid

Technically, the most notable achievement is the attainment of an impressive viral titer of approximately 1 × 10¹⁶ genome copies (GC) per liter of cell culture. Furthermore, the platform maintains a full capsid ratio (therapeutic gene properly loaded) of over 70% during the harvest stage, addressing the persistent problem of empty capsid accumulation that has plagued existing platforms. Empty capsids can trigger immunogenicity upon administration to patients, necessitating extensive and costly purification processes. Therefore, securing a high full capsid ratio from the harvest stage is considered a groundbreaking advancement in ensuring the safety and purity of gene therapies.

HEK293 Compatibility for Scalability and Cost Reduction

AAVone® 2.1 significantly reduces the amount of plasmid required and minimizes the burden on downstream processing, dramatically lowering manufacturing costs. The platform is fully compatible with the HEK293 cell line and existing bioreactor workflows commonly used in the gene therapy manufacturing industry, allowing for immediate implementation without additional capital investment. This ability to leverage existing equipment while improving process efficiency is a key factor in reducing the scale-up barriers faced by biotech companies as they transition to commercialization. Ultimately, this can lead to lower manufacturing costs, reduce the price barrier for expensive gene therapies, and improve patient access to treatment.

Expanding Partnerships and Enhancing Competitiveness in the Global AAV Market

AAVnerGene has already demonstrated the commercial value of its platform by entering into strategic licensing and supply agreements with companies such as Klotho Neurosciences (KLTO), a NASDAQ-listed company. Amidst competing platforms such as Asimov's stable producer cell line and VVector Bio's SAAVANA™, AAVone® 2.1 is establishing a unique position with its high titer and excellent safety profile. The company's efforts to secure a dominant technological advantage in the global AAV therapeutics market, which is projected to grow to approximately $20 billion by 2033, are noteworthy. In the future, the company is expected to further enhance its corporate value and investment appeal through clinical vector supply contracts and various collaborative research and development initiatives.